Green Park & Golf Ventures — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Barricade Therapeuticsbarricadetherapeutics.comin𝕏May 2026
Barricade Therapeutics is a clinical-stage oncology company developing BT-1501, an investigational once-daily oral small-molecule EBP inhibitor built on its TASIN platform to target genetic drivers of colorectal cancer.
BiotechHealthtechFort Worth, US
Neil Thapar(Chief Executive Officer)Neil C. Thapar(Co-Founder, Board Chairman, CEO & Chief Scientific Officer)John Walling(Co-Founder, SVP, CMC)Mariam E. Morris(Chief Operating Officer)Scott Jordan(Chief Financial Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.